Hussein Wafapoor, MD
Retina Specialist · Fort Myers, FLNPI 1972550622
Payments from drug & device makers
What this record shows
This record is dominated by ownership interests: $4,597 of the $4,976 with a category attached, or 92.4%. US Retina LLC accounts for 92.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2022 at $2,002 and has fallen 98.8% since, to $24 in 2024.
Across 12 payments — averaging $414.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$5K
- Dutch Ophthalmic, USA$141
- Biohaven Pharmaceuticals, Inc.$113
- Sanofi$68
- Arthrex$24
- Apellis Pharmaceuticals, Inc.$17
- plus $16 from 1 others
What the payments were for
- Food & beverage$3627%
- Education$170%
- Ownership interest$4,59792%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| US Retina LLC | 6 | $4,597 |
| Dutch Ophthalmic, USA | 1 | $141 |
| Biohaven Pharmaceuticals, Inc. | 1 | $113 |
| Sanofi | 1 | $68 |
| Arthrex | 1 | $24 |
| Apellis Pharmaceuticals, Inc. | 1 | $17 |
| Ocular Therapeutix, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,976 in reported general payments places this provider in the 55th percentile of 118 retina specialist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 15 | $8,312 |
| EysuvisLoteprednol Etabonate | 12 | $5,861 |
| Ketorolac Tromethamine | 196 | $3,579 |
| Prednisolone Acetate | 61 | $2,132 |
| Latanoprost | 143 | $1,644 |
| Brimonidine Tartrate | 84 | $966 |
| Timolol Maleate | 103 | $795 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 38 | $688 |
| Tobramycin | 57 | $315 |
| Diclofenac Sodium | 12 | $107 |
| Dorzolamide Hcl | 14 | $93 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Fort Myers
- Ashish SharmaFort Myers$10K
- Alexander EatonFort Myers$9K
- Sunil GuptaPensacola$1.8M
- Joseph NezgodaWest Palm Beach$600K
- Eduardo UchiyamaFt Lauderdale$356K
- Thomas AlbiniMiami$281K
- Audina BerrocalMiami$210K
- Philip RosenfeldMiami$206K
- John MyersPensacola$152K
- Timothy MurraySouth Miami$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.